The approval was based on two Phase 3 trials showing that more than 50% of patients receiving Skyrizi achieved an ACR20 response at 24 weeks.
Those presenting with fatigue early were likely to see it persist.
MRI-detected tenosynovitis was independently associated with progression to rheumatoid arthritis.
No differences was seen in Western Ontario and McMaster Universities Arthritis Index pain at three or 12 months with duloxetine added to usual care, or in subgroup with symptoms of centralized pain.
A significant increase in utilization and associated costs was seen among physicians’ assistants and nurse practitioners.
A panel of serum protein biomarkers was identified and evaluated for potential use in diagnostic testing for early-onset psoriatic arthritis.
Anti-CCP3 antibodies were predictive for the development of ultrasound synovitis in anti-CCP2+ at-risk individuals
No difference was seen in change in median tibial cartilage volume at 12 months for platelet-rich plasma versus saline placebo injections.
There has been a decrease in hospital discharges for sepsis, skin and soft tissue infections, and urinary tract infections among patients with psoriatic arthritis during the past several years.
Seropositivity lags after vaccination in those with rheumatic diseases but improves after second dose.
Please login or register first to view this content.